Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)-Reference-Cited by-同舟云学术

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

Published:2016-09-13 Issue:1 Volume:72 Page:246-253
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:J. Antimicrob. Chemother.

Author:

Perez-Molina J. A.,Rubio R.,Rivero A.,Pasquau J.,Suárez-Lozano I.,Riera M.,Estébanez M.,Palacios R.,Sanz-Moreno J.,Troya J.,Mariño A.,Antela A.,Navarro J.,Esteban H.,Moreno S.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/72/1/246/8497188/dkw379.pdf

Reference14 articles.

1. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study

2. Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

3. Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

4. Di Giambenedetto S , Fabbiani M , Quiros-Roldan E et al . Simplification to atazanavir/ritonavir + lamivudine versus maintaining atazanavir/ritonavir + 2NRTIs in virologically suppressed HIV-infected patients: 48-weeks data of the AtLaS-M Trial. Poster BPD1/6. 15th European AIDS Conference, 21–24 October 2015, Barcelona, Spain.

5. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain;Viruses;2024-02-06

2. Two-Drug Regimen Containing Darunavir: Metabolic Evaluation of an Old Dual Therapy;AIDS Research and Human Retroviruses;2023-12-01

3. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three‐drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study;Journal of Medical Virology;2023-10

4. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial;eClinicalMedicine;2023-06

5. Two-drug regimens for HIV treatment;The Lancet HIV;2022-12